Open AccessSuccessful brentuximab vedotin monotherapy against late relapse of classical Hodgkin lymphoma 6 years after first remission
Author(s) -
Nagashima Kana,
Kikuchi Shohei,
Iyama Satoshi,
Fujita Chisa,
Goto Akari,
Horiguchi Hiroto,
Kobune Masayoshi
Publication year - 2020
Publication title -
clinical case reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.21
H-Index - 9
ISSN - 2050-0904
DOI - 10.1002/ccr3.2688
Subject(s) - brentuximab vedotin , medicine , oncology , lymphoma , hodgkin lymphoma
Brentuximab vedotin monotherapy for late‐relapse CHL is a promising therapeutic with sustained CR benefit and avoiding potential toxicities caused by aPBSCT/HDT.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom